At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 71 enrolled
Drug / intervention
Itraconazoledrug
Likely dose
Itraconazole 200 milligramfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Clinical Efficacy and Safety of Itraconazole Injection/Oral Solution Sequential Therapy for Treatment of Invasive Pulmonary Fungal Infections
In Brief
A Phase 4 clinical trial evaluating Itraconazole for Pulmonary Fungal Infection. Completed, enrolled 71 participants.
Detailed Summary
The purpose of this study is to evaluate the efficacy and safety of itraconazole sequential therapy (intravenous injection/oral solution) in participants with invasive pulmonary fungal infections (\[IPFI\]; lung diseases caused by fungal infection).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Fungal Infection
Countries--
Collaborators--
Timeline
Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2007
Primary CompletionDec 2008
Study CompletionJan 2009
First PostedApr 2013
TodayJul 2026
First PostedApr 4, 2013
Enrollment StartJun 1, 2007
Primary CompletionDec 1, 2008
Study CompletionJan 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 13.2 years ago
Interventions
Itraconazoledrug
Itraconazole 200 milligram (mg) intravenous injection will be given twice daily for first 2 days, 200 mg once daily for the subsequent 12 days, then sequential itraconazole oral solution 200 mg twice daily will be given for 2 to 4 weeks.